Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. …
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Today | ||
![]() Could argenx SE (ARGX)’s Global Scale Give it an Edge Over Zai Lab Limited American Depositary Shares (ZLAB)? Zai Lab Limited American Depositary Shares (NASDAQ:ZLAB) and argenx SE (NASDAQ:ARGX) announced positive topline results on August 17 from their Phase 3 ALKIVIA study evaluating VYVGART Hytrulo in adults with autoimmune myositis. In the combined immune-mediated necrotizing myopathy (IMNM) and dermatomyositis (DM) population, patients treated with efgartigimod achieved a statistically significant, 15.4-point greater improvement in […] | IInsider Monkey | |
This week | ||
Asian Equities Traded in the US as American Depositary Receipts Edge Higher in Wednesday Trading Asian equities traded in the US as American depositary receipts were tracking modestly higher Wednes | MMT Newswires | |
Older | ||
Asian Equities Traded in the US as American Depositary Receipts Marginally Higher in Thursday Trading Asian equities traded in the US as American depositary receipts were marginally higher Thursday morn | MMT Newswires | |
![]() Zai Lab (ZLAB) Q2 2026 Earnings Call Transcript Zoci advances toward global registrational trials as net product revenue rises 11%. | ||
Asian Equities Traded in the US as American Depositary Receipts Edge Lower in Tuesday Trading Asian equities traded in the US as American depositary receipts were edging slightly lower Tuesday m | MMT Newswires | |
Is Zai Lab’s (ZLAB) Rising Loss on Softer Revenue Reframing Its Investment-Led Growth Story? Zai Lab Limited reported second-quarter 2026 results showing revenue of US$106.31 million versus US$109.98 million a year earlier, with net loss widening to US$50.83 million from US$40.73 million and basic loss per share increasing to US$0.50 from US$0.40. Over the first half of 2026, revenue slipped to US$205.92 million while net loss deepened to US$101.84 million, suggesting higher costs or investment needs are weighing more heavily on the income statement than a year ago. We will now... | ||
Zai Lab (ZLAB) Rebounds Following Earnings While Its Undervalued Narrative Faces A Fresh Test Zai Lab (ZLAB) stock is in focus after the company reported second quarter 2026 results, including revenue of US$106.31 million and a net loss of US$50.83 million, with wider losses than a year earlier. See our latest analysis for Zai Lab. The earnings release seems to have shifted sentiment toward Zai Lab in the short term, with an 11.69% 1 day share price return and a 27.64% 7 day share price return. However, the 1 year total shareholder return is still down 33.30%, which points to short... | ||
Zai Lab Q2 Earnings Call Highlights Zai Lab (NASDAQ:ZLAB) said its second-quarter net product revenue rose 11% sequentially to $105.8 million as the company continued to invest in a pipeline it expects to support a transition into a global biopharmaceutical business. Founder, Chairperson and CEO Samantha Du said the company is advanc | ||
Asian Equities Traded in the US as American Depositary Receipts Rise in Friday Trading; End Week Up 2% Asian equities traded in the US as American depositary receipts were tracking higher Friday morning, | MMT Newswires | |
Zai Lab Ltd (ZLAB) (Q2 2026) Earnings Call Highlights: Global Biopharma Inflection Point with U. ... Zai Lab Ltd (ZLAB) advances its DLL3 ADC pipeline with three registrational programs expected by year-end, while navigating a strategic shift toward global expansion over near-term profitability. | ||
Asian Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading Asian equities traded in the US as American depositary receipts were tracking higher Thursday mornin | MMT Newswires | |
Here's What Key Metrics Tell Us About Zai Lab Limited (ZLAB) Q2 Earnings The headline numbers for Zai Lab Limited (ZLAB) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. | ||

